Bristol-Myers Squibb Company (BMY) To Present New Remission Data On ORENCIA® (Abatacept) And Clazakizumab At The European League Against Rheumatism (EULAR) 2014 Annual Meeting
5/21/2014 9:22:55 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that 20 abstracts for Orencia® (abatacept), and clazakizumab have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism (EULAR), to be held June 11-14 in Paris, France. The extensive data being presented underscores the Company’s commitment to develop innovative treatments for patients suffering from rheumatoid arthritis (RA) and other immune-mediated diseases, including its pioneering T-cell co-stimulation modulator, Orencia, and clazakizumab, an investigational selective IL-6 cytokine inhibitor.
Help employers find you! Check out all the jobs and post your resume.
comments powered by